Thirty patients representing 5.5% of those collected by the 11q23 workshop had a t(6;11)(q27;q23). They included 27 cases of acute myeloid leukemia (AML) (M1, three cases; M2, two cases; M4, nine cases; M4/M5, one case; M5, 12 cases) of age range 3-72 years and three cases of acute lymphoblastic leukemia (ALL) (B-lineage ALL, two cases; T-ALL, one case) of age range 0.5-13 years. In 20 cases the t(6;11) was the sole abnormality. In 10 cases the recurrent additional abnormalities were extra copies of chromosomes 8, 19, 21, or the der(6). Translocation t(6;11) was identified by cytogenetics alone in 13 cases. In three cases it was confirmed by fluorescence in situ hybridization (FISH) using whole chromosome paints (wcps) 6 and 11. In a further 14 cases involvement of MLL was demonstrated by FISH, by reverse transcriptase polymerase chain reaction (RT-PCR), by Southern blotting (SB) or by a combination of these methods. One case had a direct insertion of 11 into 6-dir ins(6;11)(q27;q13q23). Molecular investigations showed that one case had a 3′ deletion of MLL. The median overall survival for the patients was 12 months, indicating a poor prognosis for patients with a t(6;11) translocation.
Introduction
The t(6;11)(q27;q23) translocation has been chiefly found in acute myeloid leukemia (AML), particularly in AML M4 (acute myelomonocytic leukemia) and AML M5 (acute monocytic leukemia). Among 32 reported cases of t(6;11) there were 10 cases of M4 and 15 of M5. 1 An association between abnormalities of the long arm of chromosome 11 and acute monocytic leukemia was first reported in 1980. 2 The first t(6;11) was identified by G-banding in a patient with M4, one of a series of 26 AMLs of differing morphology. 3 A single case report followed shortly of a patient with M5 in which the translocation was identified with R-banding. 4 It became apparent that the q23 region of chromosome 11 could be rearranged with a number of other partner chromosomes in a proportion of monocytic leukemias. 5 The t(6;11) translocation can escape recognition with conventional banding techniques and thus may well have been described in the past as a simple long arm deletion of 11, del(11)(q23). For this reason earlier series may have underestimated the incidence of the translocation. FISH techniques have proved a useful tool both for identifying the translocation 6 and for demonstrating its true frequency. 7, 8 Two in vitro cell lines bearing the translocation (one of myeloid and the other probably of lymphoid origin) have been established. 9, 10 As in many other 11q23 rearrangements the gene involved in the fusion product is MLL while its partner gene is AF6 located at band 6q27. AF6 is transcribed to an 8 kb mRNA which encodes a protein which has no similarity to the products of the other known partner genes of MLL, and may be cytoplasmic. 11 The fusion point in the AF6 cDNA has been found to be identical in four cases of AML, one case of T cell acute lymphoblastic leukemia (T-ALL) and in a myeloid cell line. 10, 11 Since the translocation breakpoints on chromosome 11 are located within the breakpoint cluster region of MLL, it is best detected by Southern blotting or by RT-PCR, although FISH using MLL probes can contribute valuable, additional information.
Materials and methods
A series of 30 patients with a t(6;11)(q27;q23) were collected as part of the EU Concerted Action 11q23 Workshop in Haematological Malignancies. Details of the inclusion criteria for cases, the type of data collected, the methods of review and the statistical tests employed are described elsewhere. 12 Clinical, survival, cytogenetic and some molecular results for the 30 patients are presented below.
Karyotypes for the following nine patients have been published previously: 88, 120, 13 
Results
Relevant clinical and laboratory data are shown for the 30 patients in Table 1 .
Clinical features
The patients represented 5.5% (30/550) of all the cases with an 11q23 rearrangement collected in this series. They included 22 adults of Ͼ15 years (median age, 40 years) and eight children of Ͻ15 years (median age, 6 years) of whom two were infants (Ͻ1 year). The median WBC of the adults was 48.6 × 10 789 Table 1 Clinical, survival, cytogenetic and molecular details of 30 patients with t(6;11)(q27; 
Immunophenotype
The immunophenotypic data was incomplete and only available for 18 of the 27 patients with AML. The patients with AML usually expressed myeloid antigens CD13 (16/17 cases) and CD33 (15/17 cases). HLA-DR was also expressed (16/17 cases) and the stem cell marker CD34 was expressed in 6/10 cases. Terminal deoxynucleotidyl transferase (TdT) was not expressed in any cases tested. Markers of monocytic differentiation were sometimes expressed, while a single case of M5 AML expressed megakaryocytic markers. Of the three patients with ALL two had pre-B disease with no aberrant expression of myeloid markers, while one had T-ALL.
Cytogenetics
The t(6;11) was the sole abnormality in two-thirds of the cases (20/30) ( Table 1) . Ten patients had additional abnormalities, in the stem line (three cases) and/or in one or more side lines (nine cases).
All three patients with M1 had additional abnormalities as did 4/8 patients with M5a. The most common additional abnormalities were extra copies of the der(6) (3/4 cases), +8 (three cases), +19 (three cases) and +21 (three cases). Normal metaphases were present in 11/30 cases.
FISH, PCR and Southern blotting
FISH and molecular results were available for 17 cases. The t(6;11) was proved by whole chromosome painting in three cases. Split MLL was confirmed by FISH alone in four cases and by FISH supported by Southern blotting and/or PCR in six further cases. MLL rearrangement was demonstrated by Southern blotting and/or PCR only, in four cases. Two cases were of particular interest. Case 102 had a variant translocationan insertion of 11 into 6 which was confirmed using a MLL probe and Southern blotting. In case 509, although MLL rearrangement was confirmed by Southern blotting, it did not appear split with FISH. Appropriate probes showed that its 3′ region had been deleted rather than translocated to chromosome 6.
Survival
The survival data for 26 patients with AML is summarised in Table 2 . One patient with AML (case 305) who died from an unrelated cause, was excluded. Complete remission was achieved by 23/26 patients but it was short-lived in most cases. The median event-free survival was only 7.8 months and the median overall survival 12 months. Two children with ALL 
Discussion
The 30 cases reported here with a t(6;11)(q27;q23) represent the largest group of cases as yet reported with this abnormality. Nine of the cases have been published previously, so we have added 21 cases to the existing literature, raising the number of published cases to over 50. The trend of most previous reports in which t(6;11) has been associated with M4 or M5 has been maintained in our series. The present study has shown for the first time that t(6;11) may also occur in infants with B-lineage ALL. One of our patients had T-ALL, an association that has been reported previously. 10, 16 The translocation was generally the sole abnormality. Additional abnormalities tended to be numerical rather than structural apart from extra copies of the der (6) . 18 Only two cases had clones with more than 50 chromosomes. The lack of additional change, particularly of structural change, has also been found in previously published cases. 1 The FISH and molecular results although incomplete were not without interest. Cytogenetic, FISH and molecular studies were discordant in three cases. A case of ALL in an infant (No. 574) in which FISH failed, had t(6;11) cytogenetically and MLL was rearranged by Southern blotting, but no fusion product was observed by RT-PCR. In case 565 the failure of both Southern blotting and RT-PCR to confirm the translocation detected by cytogenetics and FISH was probably technical. Split MLL was not demonstrated in case 509, although the Southern blot showed a rearrangement. This was due to a deletion of the 3′ part of MLL in this previously reported case. 8 Other reports indicate that MLL may be partially deleted in up to 30% of cases. 19, 20 It is probable that among the 13 cases in our series which were detected by cytogenetics alone, there may well be some with a cryptic, unidentified deletion of the MLL gene.
The insertion of chromosome 11 into chromosome 6 demonstrated by cytogenetics, Southern blotting and a split MLL signal by FISH in case 102 has also been reported previously. 13 Insertions of part of the long arm of 11 including the split MLL gene into other established fusion partners of the gene have been reported. 21 Any conclusions about survival must be tentative as the patients were few in number and had been treated at 13 different European centers. It is worth noting that the patient with T-ALL survived considerably longer than any other patient (54 months), while one patient with B-lineage ALL survived 30 months. Survival analysis for the patients with AML and t(6;11) indicated that their prognosis was poor, although this result can only be confirmed by studying a larger group of patients.
